Opening of European Commission proceedings
Aspen confirms that the European Commission has opened proceedings to investigate certain actions of Aspen Holdings and certain of its European subsidiaries. While Aspen is
Aspen’s response to the reported Competition Commission investigation
Durban – Media reports that the Competition Commission has decided to take up the Democratic Alliance’s request to investigate the alleged anti-competitive conduct of Aspen
Statement in response to press reports of 14 and 15 April 2017
In reference to the articles reported in the European press on 14 and 15 April 2017, Aspen Pharmacare Holdings Limited (“Aspen”) has the following comments:
Aspen AstraZeneca Anaesthetics Portfolio Agreement
Aspen Holdings is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has signed an agreement with AstraZeneca AB and AstraZeneca UK
Aspen demonstrates economic growth and specialized technologies contributions to Deputy President Cyril Ramaphosa
Port Elizabeth. JSE-listed Aspen, the largest pharmaceutical manufacturer in the southern hemisphere, earlier today hosted Deputy President Cyril Ramaphosa and Minister of Health Dr Aaron
Divestment of portfolio of branded and generic products to Strides entities
Aspen is pleased to announce that certain of its wholly owned Australian subsidiaries (collectively “Aspen Australia”), have entered into an agreement with Strides (Australia) Pharma
Cautionary Announcement
Shareholders are advised that Aspen is currently engaged in discussions regarding a possible acquisition of an infant nutritionals business. These discussions may have a material
Divestment of South African Business Unit to Litha
Aspen is pleased to announce that Pharmacare Limited (“Pharmacare”), a wholly owned subsidiary of Aspen Holdings and the Group’s primary South African trading company, has
Media Enquiries
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com
